Latest News and Press Releases
Want to stay updated on the latest news?
-
New York, NY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Following a challenge from GuruNanda LLC, BBB National Programs National Advertising Division determined that The Procter & Gamble Company...
-
New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Following a challenge from competitor Tailor Brands Ltd., BBB National Programs’ National Advertising Division found certain ZenBusiness Inc. filing...
-
New York, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- In a Fast-Track SWIFT challenge brought by AT&T Services, Inc., BBB National Programs’ National Advertising Division reviewed claims by Verizon...
-
New York, NY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- BBB National Programs’ National Advertising Division reviewed a challenge brought by Advantice Health regarding express claims made by XF Agencija,...
-
New York, NY, Oct. 13, 2025 (GLOBE NEWSWIRE) -- In a challenge brought by Niagen Bioscience Inc., BBB National Programs’ National Advertising Division found certain Reus Research LLC claims for its...
-
New York, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- BBB National Programs’ National Advertising Division reviewed a challenge brought by Novo Nordisk, Inc. regarding express and implied advertising...
-
New York, NY, Oct. 07, 2025 (GLOBE NEWSWIRE) -- In a challenge brought by competitor Sanofi, BBB National Programs’ National Advertising Division found certain Galderma Laboratories, L.P. itch...
-
New York, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Following a challenge submitted by competitor Vesync US Corporation (d/b/a Levoit), BBB National Programs’ National Advertising Division will refer...
-
New York, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Following a challenge submitted by competitor Vesync US Corporation (d/b/a Levoit), BBB National Programs’ National Advertising Division will refer...
-
New York, NY, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Following a challenge brought by Etekcity Corporation, BBB National Programs National Advertising Division recommended that Renpho US discontinue or...